Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Language
Year
  • 1
    Language: English
    In: Blood, 27 February 2014, Vol.123(9), pp.1284-5
    Keywords: Aniline Compounds -- Adverse Effects ; Benzamides -- Therapeutic Use ; Drug-Related Side Effects and Adverse Reactions -- Therapy ; Leukemia, Myelogenous, Chronic, BCR-Abl Positive -- Drug Therapy ; Nitriles -- Adverse Effects ; Piperazines -- Therapeutic Use ; Protein Kinase Inhibitors -- Therapeutic Use ; Pyrimidines -- Therapeutic Use ; Quinolines -- Adverse Effects
    ISSN: 00064971
    E-ISSN: 1528-0020
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Language: English
    In: PLoS ONE, 01 January 2015, Vol.10(8), p.e0136900
    Description: Myelin basic proteins (MBP) are major constituents of the myelin sheath in the central nervous system (CNS) and the peripheral nervous system (PNS). In the CNS Mbp translation occurs locally at the axon-glial contact site in a neuronal activity-dependent manner. Recently we identified the small...
    Keywords: Sciences (General)
    E-ISSN: 1932-6203
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Blood, 03/22/2012, Vol.119(12), pp.2965-2966
    Keywords: Medicine ; Biology ; Chemistry ; Anatomy & Physiology;
    ISSN: 0006-4971
    E-ISSN: 1528-0020
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: The Journal of Allergy and Clinical Immunology, 2011, Vol.128(5), pp.1113-1115.e3
    Description: For the 5- to 9-year-old age group, we can assume that the average volumes of distribution and clearances of the 3 groups were similar, since there was no significant difference in mean body mass index (Table I). [...]the lack of a statistical difference between the VHC with mask and the VHC with mouthpiece group suggests that passive inhalation does not significantly decrease lung bioavailability. [...]Lipworth et al8 did not find a difference in overnight urinary cortisol/creatinine excretion between 200 and 400 μg/day of FP delivered by large volume spacer to children, but the duration of treatment was only 4 days with each dose and urinary cortisol excretion is less sensitive than plasma cortisol concentrations.9 We, therefore, recommend initiating therapy with a lower dose of FP (176 μg/day) or reducing the dose as soon as asthma control is achieved if therapy is initiated with 440 μg/day.\n2 AA 29.5 127.0 18.3 1.10 (67) 3 22 Flovent MDI 440  39 M 9.4 AA 24.5 133.5 13.7 1.34 (72) 4 38 Flovent MDI 440  40 F 8.9 AA 37.3 132.0 21.4 1.44 (79) 3 71 Flovent MDI 220  41 F 9.6 C 39.5 142.5 19.5 1.51 (66) 26 116 Flovent MDI 440  42 M 7.5 C 23.3 127.0 14.4 1.65 (103) 5 56 Flovent MDI 440  43 M 9.0 AA 25.6 122.5 17.1 1.21 (100) 9 79 Advair Diskus 500  44 M 9.0 C 25.0 128.0 15.3 1.35 (83) 4 99 Flovent MDI 440  45 F 6.5 C 29.1 123.0 19.2 1.55 (106) 7 75 Flovent MDI 440  46 F 8.3 C 28.2 125.0 18.0 1.42 (91) 3 69 Flovent MDI 440  47 F 8.6 AA 41.8 127.4 25.8 1.41 (86) 8 70 Advair Diskus 500  48 M 8.1 C 41.8 136.0 22.6 1.66 (82) 6 26 Advair Diskus 500  49 M 6.1 C 30.2 127.0 18.7 1.61 (88) 3 326 Advair Diskus 250  Mean   8.2  31.3 129.2 18.7 1.44 (85) 6.8  421 SD   1.1  6.9 5.8 3.4 0.17 (13) 6.4  91 GM          67  95% CI          43-106  Actuator alone, 12-18 y  50 F 12.9 C 84.1 160.0 32.9 2.51 (80) 9 17.6 Flovent MDI 220  51 M 16.2 AA 87.3 167.5 31.1 3.02 (85) 7 237.5 Flovent MDI 110  52 M 15.9 C 80.9 170.2 27.9 3.77 (102) 3 16.1 Flovent MDI 440  53 M 17.9 H 70.0 172.7 23.5 3.30 (85) 3 133.9 Flovent MDI 440  54 F 15.7 AA 103.6 173.0 34.6 2.48 (100) 14 66.4 Advair Diskus 500  55 M 14.2 C 62.7 172.5 21.1 3.47 (90) 6 51.1 Pulmicort DPI 200  56 F 15.9 AA 99.4 173.0 33.2 2.47 (77) 6 78.4 Advair Diskus 500  57 F 14.4 C 65.5 159.0 25.9 3.33 (109) 13 52.5 Advair Diskus 500  58 M 12.9 C 30.3 147.3 14.0 2.22 (91) 7 81.7 Advair Diskus 500  59 M 15.1 AA 101.8 172.0 34.4 3.29 (86) 4 19.7 Pulmicort DPI 400  60 M 13.6 C 38.6 142.0 19.1 2.08 (93) 9 66.4 Flovent MDI 440  61 M 16.8 C 76.8 175.9 24.8 4.35 (107) 4 86.2 Flovent MDI 440  Mean   15.1  75.1 165.4 26.9 3.02 (92) 7  391 SD   1.6  23.3 11.1 6.7 0.68 (10) 4  135 GM          56.9  95% CI          34-96  Table E1 Individual demographic data, results, and ICS history AA, African American; C, Caucasian; DPI, dry powder inhaler; H, Hispanic; MDI, metered-dose inhaler; NR, not recorded.
    Keywords: Medicine
    ISSN: 0091-6749
    E-ISSN: 1097-6825
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Journal of Cancer Research and Clinical Oncology, Dec, 2013, Vol.139(12), p.1971(14)
    Description: Byline: Andreas Hochhaus (1), Hagop Kantarjian (2) Keywords: Dasatinib; Chronic myeloid leukemia; First-line treatment; Second-line treatment; Side effects; Early response Abstract: Purpose Dasatinib is a dual Abl/Src tyrosine kinase inhibitor (TKI) designed as a prototypic short-acting BCR--ABL-targeted TKI that inhibits BCR--ABL with greater potency compared with imatinib, nilotinib, bosutinib, and ponatinib and has been shown to have potential immunomodulatory effects. Dasatinib is approved for the treatment of all phases of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to prior imatinib treatment and first-line treatment for CML in chronic phase. In this article, the development of dasatinib as a treatment for patients with CML is reviewed. Methods This is a review of the relevant literature regarding dasatinib development in CML (2003--2013). Results Dasatinib demonstrates efficacy against most BCR--ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. Conclusion Dasatinib is an effective treatment option for patients with CML. Author Affiliation: (1) Abteilung Hamatologie/Onkologie, Klinik fur Innere Medizin II, Universitatsklinikum Jena, Erlanger Allee 101, 07740, Jena, Germany (2) Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Article History: Registration Date: 26/07/2013 Received Date: 22/07/2013 Accepted Date: 26/07/2013 Online Date: 13/08/2013
    Keywords: Chronic Myeloid Leukemia -- Drug Therapy ; Cancer Research
    ISSN: 0171-5216
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    Language: English
    In: Blood, 12 January 2012, Vol.119(2), pp.530-9
    Description: BCR-ABL overexpression and stem cell quiescence supposedly contribute to the failure of imatinib mesylate (IM) to eradicate chronic myeloid leukemia (CML). However, BCR-ABL expression levels of persisting precursors and the impact of long-term IM therapy on the clearance of CML from primitive and mature bone marrow compartments are unclear. Here, we have shown that the number of BCR-ABL-positive precursors decreases significantly in all bone marrow compartments during major molecular remission (MMR). More importantly, we were able to demonstrate substantially lower BCR-ABL expression levels in persisting MMR colony-forming units (CFUs) compared with CML CFUs from diagnosis. Critically, lower BCR-ABL levels may indeed cause IM insensitivity, because primary murine bone marrow cells engineered to express low amounts of BCR-ABL were substantially less sensitive to IM than BCR-ABL-overexpressing cells. BCR-ABL overexpression in turn catalyzed the de novo development of point mutations to a greater extent than chemical mutagenesis. Thus, MMR is characterized by the persistence of CML clones with low BCR-ABL expression that may explain their insensitivity to IM and their low propensity to develop IM resistance through kinase point mutations. These findings may have implications for future treatment strategies of residual disease in CML.
    Keywords: Antineoplastic Agents -- Therapeutic Use ; Fusion Proteins, Bcr-Abl -- Genetics ; Hematopoietic Stem Cells -- Drug Effects ; Leukemia, Lymphocytic, Chronic, B-Cell -- Genetics ; Piperazines -- Therapeutic Use ; Pyrimidines -- Therapeutic Use
    ISSN: 00064971
    E-ISSN: 1528-0020
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.5164-5164
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: German
    In: TumorDiagnostik & Therapie, 2016, Vol.37(01), pp.26-29
    ISSN: 0722-219X
    E-ISSN: 1439-1279
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Article
    Article
    Language: German
    In: Deutsche medizinische Wochenschrift (1946), October 2011, Vol.136(40), pp.2007-10
    Keywords: Antineoplastic Agents -- Therapeutic Use ; Leukemia, Myelogenous, Chronic, BCR-Abl Positive -- Drug Therapy
    ISSN: 00120472
    E-ISSN: 1439-4413
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Language: German
    In: Hansa, 2012, Vol.149(7), pp. 41-45
    ISSN: 00177504
    Source: Deutsche Zentralbibliothek für Wirtschaftswissenschaften
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages